Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer

Дата публикации: 25-06-2026 00:00:00

This secondary analysis of a randomized clinical trial evaluates 5-year outcomes and characterizes circulating tumor DNA dynamics in patients with ERBB2-positive breast cancer treated with 12 weeks of neoadjuvant paclitaxel, trastuzumab, and pertuzumab.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Less Can Be More by Circulating Tumor DNA Use in ERBB2 -Positive Breast Cancer	0	7	25-06-2026
2	Circulating Tumor DNA in Early Breast Cancer	0	9.02	01-07-2026
3	Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors	0	7	25-06-2026
4	Benefit of Adjuvant Chemotherapy in Patients with ctDNA-positive Resected Stage II Colon Cancer	0	14.76	30-07-2026
5	Tissue-Free vs Tumor-Informed Circulating Tumor DNA Assays in Early Triple Negative Breast Cancer	0	12.99	13-08-2026
6	Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer	0	10	28-07-2026
7	Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma	5	7	30-06-2026
8	Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy	0	7	18-06-2026
9	Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC	0	12.4	23-07-2026
10	Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL	0	14.76	06-08-2026

Схожие патенты

#	Наименование патента
1	TREATMENT OF HER2-POSITIVE BREAST CANCER

Классификация: Пресс-релизы. Схожий патент: 1. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.